WHWK

Whitehawk Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.76
52-Week Range: $1.87 – $5.50
Market Cap: $210.93M
P/E (TTM): —
EPS (TTM): -1.14
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.15
PEG Ratio: —
Return on Equity: -44.98%
Return on Assets: -28.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 17.38
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-43.61M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $20.95M

WHWK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$15.22M	$24.35M	$25.98M	$7.14M
Cost of Revenue	$1.33M	$2.81M	$3.02M	$760.00K
Gross Profit	$13.88M	$21.55M	$22.96M	$6.38M
Research & Development	$32.66M	$48.93M	$51.03M	$90.96M
Selling, General & Admin	$40.18M	$44.55M	$36.75M	$29.82M
Operating Expenses	$72.84M	$93.48M	$87.78M	$120.78M
Operating Income	-$58.96M	-$71.93M	-$64.82M	-$114.40M
EBITDA	-$60.12M	-$65.36M	-$63.34M	-$20.52M
Pretax Income	-$60.51M	-$65.77M	-$63.69M	-$20.60M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$60.51M	-$65.77M	-$63.69M	-$20.60M
Diluted EPS	-2.69	-2.44	-2.36	-0.33
Diluted Shares	22.51M	26.92M	27.03M	61.89M

WHWK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$39.02M	$62.89M	$28.67M	$37.57M
Receivables	$1.86M	$5.49M	$5.90M	$0.00
Inventory	$1.86M	$6.43M	$5.31M	$0.00
Current Assets	$180.03M	$124.59M	$61.29M	$149.01M
Total Assets	$184.24M	$132.42M	$70.32M	$150.83M
Current Liabilities	$18.84M	$26.39M	$17.07M	$14.52M
Total Debt	$1.66M	$1.27M	$833.00K	$0.00
Total Liabilities	$25.86M	$27.23M	$17.84M	$14.52M
Retained Earnings	-$203.20M	-$268.96M	-$332.65M	-$353.25M
Shareholders' Equity	$158.38M	$105.19M	$52.48M	$136.31M
Working Capital	$161.19M	$98.19M	$44.21M	$134.49M

WHWK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$49.64M	-$59.66M	-$59.55M	-$97.43M
Capital Expenditure	-$444.00K	-$3.97M	-$1.65M	-$552.00K
Free Cash Flow	-$50.08M	-$63.63M	-$61.20M	-$97.98M
Depreciation & Amortisation	$159.00K	$169.00K	$193.00K	$79.00K
Stock-Based Compensation	$9.64M	$11.95M	$10.84M	$9.87M
Investing Cash Flow	-$132.89M	$83.21M	$25.20M	$11.89M
Financing Cash Flow	$72.62M	$326.00K	$130.00K	$94.38M
Dividends Paid	$0.00	—	—	—
Net Change in Cash	-$109.91M	$23.87M	-$34.22M	$8.83M

WHWK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$7.14M	$0.00	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$760.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Gross Profit	$6.38M	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$8.79M	$48.81M	$14.35M	$19.02M	$17.23M	$12.89M
Selling, General & Admin	$12.81M	$5.94M	$5.20M	$5.87M	$6.29M	$5.22M
Operating Expenses	$21.60M	$54.75M	$19.55M	$24.89M	$23.52M	$18.11M
Operating Income	-$15.22M	-$54.75M	-$19.55M	-$24.89M	-$23.52M	-$18.11M
EBITDA	-$15.16M	-$54.73M	-$17.74M	-$23.25M	-$23.52M	-$18.11M
Pretax Income	$73.02M	-$52.62M	-$17.75M	-$23.25M	-$22.19M	-$16.64M
Income Tax	$0.00	$0.00	—	—	$0.00	$0.00
Net Income	$73.02M	-$52.62M	-$17.75M	-$23.25M	-$22.19M	-$16.64M
Diluted EPS	1.83	-0.76	-0.26	-0.34	-0.32	-0.20
Diluted Shares	39.93M	69.08M	69.20M	69.21M	69.24M	82.89M

WHWK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$227.57M	$144.94M	$37.93M	$37.57M	$34.79M	$85.23M
Receivables	$0.00	$0.00	$0.00	$0.00	—	—
Inventory	$0.00	$0.00	$0.00	$0.00	—	—
Current Assets	$232.61M	$178.67M	$165.04M	$149.01M	$125.55M	$192.41M
Total Assets	$234.00M	$180.82M	$167.02M	$150.83M	$127.23M	$193.99M
Current Liabilities	$12.27M	$8.76M	$9.85M	$14.52M	$11.06M	$11.07M
Total Debt	$0.00	$0.00	$0.00	$0.00	—	—
Total Liabilities	$12.27M	$8.76M	$9.85M	$14.52M	$11.06M	$11.07M
Retained Earnings	-$259.64M	-$312.25M	-$330.00M	-$353.25M	-$375.44M	-$392.08M
Shareholders' Equity	$221.73M	$172.07M	$157.17M	$136.31M	$116.17M	$182.93M
Working Capital	$220.34M	$169.91M	$155.19M	$134.49M	$114.49M	$181.34M

WHWK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$11.86M	-$52.96M	-$15.38M	-$17.23M	-$22.21M	-$14.53M
Capital Expenditure	-$551.00K	-$1.00K	—	—	—	—
Free Cash Flow	-$12.41M	-$52.96M	-$15.38M	-$17.23M	-$22.21M	-$14.53M
Depreciation & Amortisation	$57.00K	$16.00K	$5.00K	$1.00K	$1.00K	$1.00K
Stock-Based Compensation	$1.68M	$3.09M	$2.72M	$2.39M	$2.19M	$1.52M
Investing Cash Flow	$115.50M	-$28.83M	-$91.63M	$16.85M	$19.43M	-$16.87M
Financing Cash Flow	$95.20M	-$850.00K	$0.00	$25.00K	$0.00	$81.84M
Net Change in Cash	$198.84M	-$82.63M	-$107.00M	-$363.00K	-$2.78M	$50.44M

Market Snapshot

About

Whitehawk Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company utilizes proprietary drug discovery platforms to identify and advance novel small molecule therapeutics targeting critical pathways in disease progression.